About
Technology
Issues
FAQ
Search
Profile
Schools
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Scientometrics
Avg. Impact Factor
Discipline Ranks
h
-index
g
-index
★★
Articles
★★★
Articles
Article Citations
Citation Distribution
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Institutions
›
Ventana Medical Systems
›
top-articles
Ventana Medical Systems
110
(top 1%)
papers
2.9K
(top 1%)
citations
23
(top 1%)
h
-index
53
(top 1%)
g
-index
114
all documents
3.1K
doc citations
883
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
Cell
2018
609
2
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
JAMA Oncology
2019
557
3
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Journal of Clinical Oncology
2018
350
4
Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer
Journal of Thoracic Oncology
2012
147
5
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
Applied Immunohistochemistry and Molecular Morphology
2019
144
6
High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma
1996
94
7
Fully automated 5-plex fluorescent immunohistochemistry with tyramide signal amplification and same species antibodies
Laboratory Investigation
2017
84
8
Aurora-A over-expression in high-grade PIN lesions and prostate cancer
Prostate
2005
71
9
PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer
Breast Journal
2018
65
10
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study
Breast Cancer Research and Treatment
2014
59
11
Effect of Delayed Formalin Fixation on Estrogen and Progesterone Receptors in Breast Cancer
American Journal of Clinical Pathology
2010
51
12
Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma
Blood
2012
49
13
Novel dual-color immunohistochemical methods for detecting ERG–PTEN and ERG–SPINK1 status in prostate carcinoma
Modern Pathology
2013
47
14
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib
Journal of Thoracic Oncology
2017
46
15
Evaluating HPV‐negative CIN2+ in the ATHENA trial
International Journal of Cancer
2016
43
16
BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma
Human Pathology
2014
34
17
Metallographic in situ hybridization
Human Pathology
2007
32
18
Characterization of monoclonal antibodies against stromelysin-3 and their use to evaluate stromelysin-3 levels in breast carcinoma by semi-quantitative immunohistochemistry
International Journal of Cancer
1995
31
19
Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).
Journal of Clinical Oncology
2017
30
20
Colorimetric In Situ Hybridization Identifies MYC Gene Signal Clusters Correlating With Increased Copy Number, mRNA, and Protein in Diffuse Large B-Cell Lymphoma
American Journal of Clinical Pathology
2013
29
21
Low GILT Expression is Associated with Poor Patient Survival in Diffuse Large B-Cell Lymphoma
Frontiers in Immunology
2013
28
22
Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair–Proficient Stage II Colon Cancer
Clinical Cancer Research
2016
26
23
Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer
Breast Cancer Research and Treatment
2017
26
24
Characterization of Natural Product Chemopreventive Agents
2005
26
25
Clinical validation of p16/Ki‐67 dual‐stained cytology triage of
HPV
‐positive women: Results from the
IMPACT
trial
International Journal of Cancer
2022
25
26
The Utility of BRAF V600E Mutation-Specific Antibody VE1 for the Diagnosis of Hairy Cell Leukemia
American Journal of Clinical Pathology
2015
23
27
The CD117 Immunohistochemistry Tissue Microarray Survey for Quality Assurance and Interlaboratory Comparison: A College of American Pathologists Cell Markers Committee Study
Archives of Pathology and Laboratory Medicine
2006
23
28
Epidermal growth factor receptor mutation‐specific immunohistochemical antibodies in lung adenocarcinoma
Histopathology
2014
22
29
Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients.
Journal of Clinical Oncology
2015
22
30
Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer
Applied Immunohistochemistry and Molecular Morphology
2021
21
31
ERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosis
Journal of Pathology: Clinical Research
2016
18
32
Automated Brightfield Dual-Color In Situ Hybridization for Detection of Mouse Double Minute 2 Gene Amplification in Sarcomas
Applied Immunohistochemistry and Molecular Morphology
2011
17
33
The business value and cost–effectiveness of genomic medicine
Personalized Medicine
2012
17
34
ERG Overexpression and PTEN Status Predict Capsular Penetration in Prostate Carcinoma
Prostate
2013
17
35
Identification of HER2 Immunohistochemistry-Negative, FISH-Amplified Breast Cancers and Their Response to Anti-HER2 Neoadjuvant Chemotherapy
American Journal of Clinical Pathology
2019
16
36
Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer
Journal of Thoracic Oncology
2012
15
37
Automated Multiplexing Quantum Dots in Situ Hybridization Assay for Simultaneous Detection of ERG and PTEN Gene Status in Prostate Cancer
Journal of Molecular Diagnostics
2013
15
38
HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
American Journal of Clinical Pathology
2017
15
39
Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788
Clinical Cancer Research
2012
14
40
Delta-like Protein 3 Prevalence in Small Cell Lung Cancer and DLL3 (SP347) Assay Characteristics
Archives of Pathology and Laboratory Medicine
2019
12
41
The combined positive impact of Lean methodology and Ventana Symphony autostainer on histology lab workflow
BMC Clinical Pathology
2010
11
42
Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer
Anticancer Research
2018
11
43
Time Gated Luminescence Imaging of Immunolabeled Human Tissues
Analytical Chemistry
2017
10
44
Declines Noted in Cognitive Processes and Association With Achievement Among Children With Leukemia
Oncology Nursing Forum
2017
9
45
Interpathologist Diagnostic Agreement for Non–Small Cell Lung Carcinomas Using Current and Recent Classifications
Archives of Pathology and Laboratory Medicine
2018
9
46
Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer
Annals of Oncology
2018
9
47
Intratumoral CD3+ and CD8+ T-Cell Densities in Patients With DNA Mismatch Repair–Deficient Metastatic Colorectal Cancer Receiving Programmed Cell Death-1 Blockade
JCO Precision Oncology
2019
9
48
Final analysis of stage 1 data from a randomized phase II study of PEGPH20 plus nab-Paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients (pts), utilizing Ventana companion diagnostic assay.
Journal of Clinical Oncology
2016
9
49
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis
Clinical Lymphoma, Myeloma and Leukemia
2021
8
50
Abstract B001: Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab
2016
8
site/software ©
exaly
; All materials licenced under
CC by-SA
.